0001209191-20-007695.txt : 20200207 0001209191-20-007695.hdr.sgml : 20200207 20200207185424 ACCESSION NUMBER: 0001209191-20-007695 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200207 DATE AS OF CHANGE: 20200207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gano Kyle CENTRAL INDEX KEY: 0001567160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 20588870 MAIL ADDRESS: STREET 1: NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-05 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001567160 Gano Kyle 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Business Development Off Common Stock 2020-02-05 4 S 0 1013 103.0072 D 87204 D Common Stock 2020-02-05 4 S 0 703 103.0347 D 87838 D Common Stock 2020-02-05 4 S 0 1974 103.0812 D 89614 D Common Stock 2020-02-06 4 S 0 1000 101.413 D 90514 D Stock Option 102.90 2020-02-06 4 A 0 76683 0.00 A 2030-02-06 Common Stock 76683 76683 D Restricted Stock Unit 2020-02-06 4 A 0 12148 0.00 A Common Stock 12148 12148 D Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.16 to $105.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Includes a total of 459 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 312 shares on February 28, 2019 and 147 shares on August 30, 2019. Sale of 703 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.86 to $105.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.73 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. /s/ Darin Lippoldt, Attorney-in-Fact 2020-02-07